

Supplementary Table 1 Pharmacokinetic parameters^a of veliparib and its main metabolite (A-925088) when veliparib was given orally alone on cycle 2 day -1 or in combination with irinotecan on cycle 2 day 8

Dose (mg)	n	Day	T _{max} (h)	C _{max} (ng/ml)	T _{last} (h)	C _{last} (ng/ml)	AUC _{last} (ng/ml*h)	AUC _{0-∞} (ng/ml*h)	T _{1/2} (h)	CL/F ^b (L)	A-925088 AUC _{last} (ng/ml*h)	AUC ratio A-925088 /veliparib
10	6	-1	2.1±1.2 (83%)	32±18 (55%)	9.6±0.6 (7%)	9±4 (42%)	154±51 (33%)	222±63 (28%)	5.0±1.8 (35%)	48±13 (27%)	140±97 (69%)	1.0±1.0 (97%)
10	6	8	2.5±1.4 (55%)	50±20 (40%)	7.9±2.7 (34%)	23±6 (26%)	259±96 (37%)			45±23 (52%)	100±69 (69%)	0.8±0.5 (70%)
20	7	-1	2.4±1.9 (77%)	170±62 (36%)	24.4±6.7 (27%)	13±18 (145%)	1101±307 (28%)	1236±332 (27%)	6.1±1.1 (17%)	17±4 (22%)	213±93 (44%)	0.2±0.1 (49%)
20	7	8	2.4±1.3 (55%)	244±101 (41%)	9.3±0.9 (10%)	94±34 (36%)	1349±402 (30%)			16±4 (25%)	226±25 (55%)	0.2±0.1 (77%)
40	8	-1	1.9±1.2 (60%)	366±145 (40%)	24.3±6.1 (25%)	31±37 (117%)	2558±752 (29%)	3067±1280 (42%)	7.7±5.3 (68%)	14±4 (25%)	380±109 (29%)	0.2±0.0 (19%)
40	8	8	2.1±1.1 (53%)	576±103 (18%)	9.7±0.6 (6%)	187±58 (31%)	3252±551 (17%)			13±2 (17%)	471±275 (58%)	0.2±0.1 (46%)
50	5	-1	1.0±0.3 (34%)	842±250 (30%)	27.8±1.9 (7%)	28±40 (144%)	4245±784 (42%)	4611±2369 (51%)	6.6±2.2 (33%)	13±5 (41%)	763±205 (27%)	0.2±0.0 (12%)
50	4	8	2.8±0.9 (31%)	760±124 (16%)	9.7±0.5 (5%)	199±41 (20%)	4636±692 (15%)			10±2 (21%)	578±391 (68%)	0.2±0.0 (3%)

^a Pharmacokinetic parameters were estimated using non-compartmental analysis with WinNonlin (Pharsight). Data are expressed as the mean ± standard deviation with coefficient variation in the parenthesis.

^b CL/F on day 8 was calculated as dose/AUC_{last}.

Abbreviations: C_{max}, maximum plasma concentration; T_{max}, time to achieve C_{max}; T_{last}, last sampling time point; C_{last}, last measurable concentration; AUC_{last}, area under the plasma concentration time curve from time 0 to the last sampling time point; AUC_{0-∞}, area under the plasma concentration time curve from time 0 to infinity; T_{1/2}, terminal elimination half-life; CL/F, apparent oral clearance.